1. CHLAMYDIA/GC RNA, TMA,
Includes
Chlamydia trachomatis, Neisseria gonorrhoeae
Methodology
Dual Kinetic Assay (DKA) • Target Capture • Transcription-Mediated Amplification (TMA)
This test was performed using the APTIMA® COMBO2 Assay (GEN-PROBE).
Clinical Significance
C. trachomatis infections are the leading cause of sexually transmitted diseases in the United States. C. trachomatis is known to cause cervicitis, pelvic inflammatory disease (PID), epididymitis and proctitis. It is also the most frequent cause of non-gonococcal urethritis in men. Among women, the consequences of Chlamydialinfections are severe if left untreated.
Patient Preparation
Urine specimens: The patient should not have urinated for at least one hour prior to specimen collection. Female patients should not cleanse the labial area prior to providing the specimen.
6. SYPHILIS
Includes
If RPR Screen is reactive, RPR titer will be performed at an additional charge (CPT code(s): 86593).
Limitations
False-positive results have been associated in patients with infections, pregnancy, autoimmune disease, old age, Gaucher disease, and malignancy.
Clinical Significance
This is a non-treponemal screening test for syphilis. False positive results may occur due to systemic lupus erythematosus, leprosy, brucellosis, atypical pneumonia, typhus, yaws, pinta, or pregnancy. Monitoring of RPR is helpful in assessing effectiveness of therapy.
3. HSV TYPE 1/2, IGM W/RF - aka Herpes
If HSV 1 IgM screen is positive, HSV 1 IgM Titer will be performed at an additional charge (CPT code(s): 86695).
If HSV 2 IgM Screen is positive, HSV 2 IgM Titer will be performed at an additional charge (CPT code(s): 86696).
Methodology
Immunofluorescence Assay (IFA)
Clinical Significance
HSV IgM is detectable in serum from >90% of patients with primary HSV infection; However, HSV IgM is also found in 30% of patients with reactivated HSV.
Alternative Name(s)
Herpes Simplex Virus Serum,Herpes 1/2 IgM, Serum